Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- New IDF DM Management GL Stresses Importance of Postprandial Glucose
November 19, 2007
- Education on Vaccination for Uterine Cervical Cancer Needed
November 19, 2007
- All Antidepressants to Warn of Risk of Suicide in Patients Aged 24 or Younger
November 12, 2007
- Former Tanabe Seiyaku: Remicade Drives Sales, Profits
November 12, 2007
- Concerta Approved for ADHD, Depression Deleted as Indication for Ritalin
November 12, 2007
- Eisai: Record-High Sales, Profits Driven by Aricept
November 12, 2007
- JMA Calls For Reimbursement of Generics Used Off-label
November 12, 2007
- Debiopharm Licenses DACH-platin MediCelle from NanoCarrier
November 12, 2007
- Sawai Revises Business Forecasts Downward
November 12, 2007
- Taisho Concludes LOI with Pfizer on TS-032
November 12, 2007
- Different Views Presented on NHI Price Listing for Generics 4 Times a Year
November 12, 2007
- About 80% of Intestinal Flora Species Remain Unknown
November 12, 2007
- Korosho to Promote Elimination of Films from Imaging Diagnosis
November 12, 2007
- 11 Generics Receive NHI Price Listing in the 1st Biannual Listing
November 12, 2007
- Pfizer Japan Begins Restructuring to Spur Simultaneous Global Development
November 12, 2007
- MEDICAL DEVICE NEWS IN BRIEF
November 12, 2007
- BUSINESS NEWS IN BRIEF
November 12, 2007
- STPO PRESS／Prasugrel Significantly Reduces Risk of Serious CV Events Compared to Clopidogrel
November 12, 2007
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
November 12, 2007
- TOPICS 2 articles
November 12, 2007
ページ
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…